Actively Recruiting
Evaluating Acute Lymphoblastic Leukemia-Based Treatment in Patients Aged 14 and Older with Acute Leukemia of Ambiguous Lineage
Led by Institute of Hematology & Blood Diseases Hospital, China · Updated on 2025-08-06
50
Participants Needed
1
Research Sites
78 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the clinical effectiveness of chemotherapy based on acute lymphoblastic leukemia ALL in patients diagnosed with acute leukemia of ambiguous lineage. This prospective, single arm, open label clinical trial will enroll 50 patients aged 14 years and older. The study also investigates how genetic abnormalities and minimal residual disease MRD impact patients prognosis. Participants will receive ALL-based chemotherapy, which includes drugs such as vincristine, daunorubicin, cyclophosphamide, L-Asparaginase, prednisone, mercaptopurine, methotrexate, dexamethasone, and tyrosine kinase inhibitors for those with the t922 genetic abnormality. Patients who achieve complete remission CR may receive allogeneic hematopoietic stem cell transplantation HSCT otherwise, they will complete consolidation chemotherapy. During the trial, participants will be monitored for overall survival up to five years, relapse-free survival also up to five years, complete remission rates up to 2.5 years, and mortality within 60 days. The study includes ongoing assessments of genetic factors and minimal residual disease to understand their effects on outcomes. Participants will undergo regular clinical evaluations and laboratory tests to track treatment response and safety throughout the study period.
CONDITIONS
Brief Title
Efficacy of Acute Lymphoblastic Leukemia-Based Therapy in Treating Patients With Acute Leukemia of Ambiguous Lineage
Research Team
J
Jianxiang Wang, Dr
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here